UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

~~July~~August 2724, 2010 (Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

	Michigan		1-31773		38-2505723
	(State or other jurisdiction of incorporation)		(Commission file number)		(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 23.02. Unregistered ~~Results~~Sales of ~~Operations~~Equity ~~and Financial Condition~~Securities

OnAs ~~July~~of 27August 24, 2010, registrant ~~announced~~issued ~~its~~544,000 ~~results~~shares of ~~operations~~common ~~for~~stock to Sun Pharma Global, Inc. (“Sun Global”) as a result of the ~~first~~conversion ~~quarter~~by Sun Global of ~~Fiscal~~544,000 ~~2011~~shares of Series B Preferred Stock. 544,000 asshares ~~set~~of ~~forth~~Series B Preferred Stock were originally issued to Sun Global on August 13, 2007 in connection with the ~~press~~transfer ~~release~~of ~~included~~one asproduct ~~Exhibit~~on ~~99.1~~such ~~hereto~~date ~~and~~pursuant ~~incorporated~~to ~~herein~~registrant’s byproducts ~~reference~~agreement with Sun Global dated November 21, 2002.

~~Item~~The ~~5.02.~~Series ~~Departure~~B Preferred Stock may be converted into common stock on a one-for-one basis after three years from the date of ~~Directors~~issuance or ~~Certain~~following ~~Officers;~~a ~~Election~~person of(other ~~Directors;~~than ~~Appointment~~Sun ofPharmaceutical ~~Certain~~Industries ~~Officers;~~Limited ~~Compensatory~~and ~~Arrangements~~its ofaffiliates) ~~Certain~~acquiring ~~Officers~~control of registrant.

~~(c) On~~The ~~July~~common ~~23,~~stock ~~2010,~~was ~~Gurpartap~~issued ~~Singh~~pursuant ~~Sachdeva,~~to ~~41,~~an ~~was~~exemption ~~appointed~~from ~~the~~registration ~~Chief~~under ~~Operating~~Section ~~Officer~~4(2) of the ~~Company,~~Securities asAct ~~set~~of ~~forth in the press release included as Exhibit 99~~1933.~~2 and incorporated herein by reference.~~

Item 9.01. Financial Statements and Exhibits.

d. Exhibits.

Exhibit No. Description

99.1 Press release of Caraco Pharmaceutical Laboratories, Ltd., dated July 27, 2010 announcing its results of operations for the first quarter of Fiscal 2011.

99.2 Press release of Caraco Pharmaceutical Laboratories, Ltd., dated July 27, 2010 announcing the appointment of Chief Operating Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date: July 28, 2010	By:	/s/ Jitendra N. Doshi
Date:	August 30, 2010	By:	/s/ Jitendra N. Doshi
		~~Jitendra N. Doshi~~	Jitendra N. Doshi
		~~Chief Executive Officer~~	Chief Executive Officer

~~Exhibit Index~~2

99.1 Press release of Caraco Pharmaceutical Laboratories, Ltd., dated July 27, 2010 announcing its results of operations for the first quarter of Fiscal 2011.

99.2 Press release of Caraco Pharmaceutical Laboratories, Ltd., dated July 27, 2010 announcing the appointment of Chief Operating Officer.

Filing Compare · CARACO PHARMACEUTICAL LABORATORIES LTD